Form 4: Kestra Medical Director Acquires 10,909 RSUs

Kestra Medical Technologies Director and 10% owner, Jeffrey Lawrence Schwartz, acquired 10,909 restricted stock units vesting in September 2026.

Summary

• Jeffrey Lawrence Schwartz, a Director and 10% Owner of Kestra Medical Technologies, Ltd. (KMTS), acquired 10,909 restricted stock units (RSUs).
• These RSUs entitle Mr. Schwartz to receive one common share of the Issuer for each unit.
• The RSUs are scheduled to vest on September 4, 2026, contingent upon Mr. Schwartz's continued service to the company.
• Following this transaction, Mr. Schwartz directly holds 10,909 common shares (represented by the RSUs) and indirectly holds 27,019,225 common shares.
• The indirect holdings consist of 7,109,944 common shares held by Bain Charger Holdings, L.P. and 19,909,281 common shares held by West Affum Holdings, L.P.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a director and significant owner is generally viewed positively as it aligns the insider's interests with the company's long-term performance, indicating confidence.

Positives

• The acquisition of restricted stock units by a director and 10% owner signals continued alignment of management's interests with long-term shareholder value.
• The vesting schedule, tied to continued service, incentivizes the director's ongoing commitment to the company's performance.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the restricted stock units, which is contingent on continued service.

Management Comments

• Mr. Schwartz disclaims beneficial ownership of the securities held by Bain Charger and West Affum except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, common in the medical technology sector and other industries, where executive and board compensation often includes equity awards like restricted stock units to align leadership incentives with company performance.

Related Party Transactions

• Jeffrey Lawrence Schwartz is a Partner of Bain Capital Investors, LLC, which is the general partner of Bain Charger Holdings, L.P.
• Bain Charger Holdings, L.P. directly holds 7,109,944 common shares of Kestra Medical Technologies, Ltd.
• Bain Charger is the sole shareholder of West Affum GP Ltd., which is the general partner of West Affum Holdings, L.P.
• West Affum Holdings, L.P. directly holds 19,909,281 common shares of Kestra Medical Technologies, Ltd.
• Mr. Schwartz may be deemed to share voting and dispositive power over the securities held by Bain Charger and West Affum due to his role at Bain Capital Investors, LLC, but disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive signal, indicating management's commitment and alignment with long-term company success.
• Employees may see this as a standard compensation practice for senior leadership, potentially reinforcing confidence in the company's direction.

Next Steps

• The 10,909 restricted stock units are expected to vest on September 4, 2026, converting into common shares, provided Mr. Schwartz continues his service through that date.

Key Dates

Recommendation

While the acquisition of restricted stock units by a director and 10% owner is a positive signal of alignment and confidence, it is a compensation event rather than an open market purchase based on a valuation decision. This single Form 4 filing, without additional financial or strategic context, supports a 'hold' recommendation, acknowledging the positive insider alignment but not necessarily indicating an immediate 'buy' opportunity based solely on this transaction.

Keywords

Kestra Medical Technologies, KMTS, Jeffrey Lawrence Schwartz, Restricted Stock Units, RSUs, Insider Transaction, Form 4, Director Compensation, Bain Capital